双极射频局灶消融治疗前列腺癌的前瞻性开发研究
这项IDEAL 2期前瞻性研究评估了双极射频消融系统(Encage™)对MRI可见的临床显著局限性前列腺癌的局灶消融早期疗效。共20例患者接受治疗,6个月活检显示80%(16/20)无显著局限性前列腺癌,患者报告结局显示泌尿、勃起和肠道副作用发生率低,无严重不良事件。
要点
- 双极射频局灶消融后6个月,80%(16/20)患者靶向活检无显著前列腺癌。
- 患者报告结局显示泌尿、勃起和肠道副作用发生率低,无严重不良事件。
- 研究为IDEAL 2期前瞻性开发研究,样本量小,需进一步验证。
核心结论
- 双极射频局灶消融对MRI可见的显著局限性前列腺癌显示出早期消融疗效,且泌尿生殖系和直肠副作用发生率低。
研究设计与样本
- 前瞻性IDEAL 2期开发研究(Focal Prostate Radiofrequency Ablation,NCT02294903),纳入21例初治、单一显著局限性前列腺癌且与mpMRI可见病灶一致的患者,20例接受干预。
主要发现
- 20例接受干预的患者中,16例(80%)在6个月靶向活检时无显著局限性前列腺癌,与mpMRI结果一致。
- 患者报告结局分析显示副作用发生率低,且无严重不良事件。
关键数值与推荐
- 基线中位年龄66岁(IQR 63-69),术前中位PSA 7.9 ng/ml(IQR 5.3-9.6)。
- 18例(90%)为Gleason 7疾病,中位最大癌灶7 mm(IQR 5-10),中位mpMRI病灶体积2.8 cc(IQR 1.4-4.8)。
- 靶向活检中位针数6针(IQR 5-8)。
临床怎么用
- 双极射频局灶消融可作为MRI可见显著局限性前列腺癌的局灶治疗选择,早期疗效可接受且副作用低。
局限性
- 样本量小(20例接受干预),随访仅6个月,为按方案分析,需更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We determined the early efficacy of bipolar radiofrequency ablation with a coil design for focal ablation of clinically significant localized prostate cancer visible at multiparametric magnetic resonance imaging. MATERIALS AND METHODS: A prospective IDEAL phase 2 development study (Focal Prostate Radiofrequency Ablation, NCT02294903) recruited treatment-naïve patients with a single focus of significant localized prostate cancer (Gleason 7 or 4 mm or more of Gleason 6) concordant with a lesion visible on multiparametric magnetic resonance imaging. Intervention was a focal ablation with a bipolar radiofrequency system (Encage™) encompassing the lesion and a predefined margin using nonrigid magnetic resonance imaging-ultrasound fusion. Primary outcome was the proportion of men with absence of significant localized disease on biopsy at 6 months. Trial followup consisted of serum prostate specific antigen, multiparametric magnetic resonance imaging at 1 week, and 6 and 12 months post-ablation. Validated patient reported outcome measures for urinary, erectile and bowel functions, and adverse events monitoring system were used. Analyses were done on a per-protocol basis. RESULTS: Of 21 patients recruited 20 received the intervention. Baseline characteristics were median age 66 years (IQR 63-69) and preoperative median prostate specific antigen 7.9 ng/ml (5.3-9.6). A total of 18 patients (90%) had Gleason 7 disease with median maximum cancer 7 mm (IQR 5-10), for a median of 2.8 cc multiparametric magnetic resonance imaging lesions (IQR 1.4-4.8). Targeted biopsy of the treated area (median number of cores 6, IQR 5-8) showed absence of significant localized prostate cancer in 16/20 men (80%), concordant with multiparametric magnetic resonance imaging. There was a low profile of side effects at patient reported outcome measures analysis and there were no serious adverse events. CONCLUSIONS: Focal therapy of significant localized prostate cancer associated with a magnetic resonance imaging lesion using bipolar radiofrequency showed early efficacy to ablate cancer with low rates of genitourinary and rectal side effects.
引用
- Orczyk C, Barratt D, Brew-Graves C, et al. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. J Urol. 2020. PMID: 33315505. doi:10.1097/JU.0000000000001567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。